ARS Pharmaceuticals Inc
SPRY
Company Profile
Business description
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Contact
11682 El Camino Real
Suite 300
San DiegoCA92130
USAT: +1 858 771-9307
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
200
Stocks News & Analysis
stocks
Our view after Coles’ shares plunge
Shares dropped 8% after reporting results for the September 2026 quarter.
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,973.10 | 52.30 | -0.58% |
| CAC 40 | 7,969.42 | 0.58 | -0.01% |
| DAX 40 | 25,818.21 | 221.47 | -0.85% |
| Dow JONES (US) | 51,770.31 | 572.25 | -1.09% |
| FTSE 100 | 10,729.78 | 7.71 | 0.07% |
| HKSE | 23,525.36 | 230.94 | 0.99% |
| NASDAQ | 25,437.00 | 747.73 | -2.86% |
| Nikkei 225 | 63,197.02 | 93.09 | -0.15% |
| NZX 50 Index | 13,640.99 | 156.01 | -1.13% |
| S&P 500 | 7,580.07 | 140.32 | -1.82% |
| S&P/ASX 200 | 8,857.70 | 50.40 | -0.57% |
| SSE Composite Index | 3,610.16 | 11.15 | 0.31% |